Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV

Effect of High-Dose Vitamin D3 on Alveolar Macrophage Function, LL-37, and Oxidative Stress in Smokers and Non-Smokers With and Without HIV

Supplementation with vitamin D improves HIV+ macrophages phagocytosis in vitro. There is evidence to suggest that administering vitamin D can in fact improve immune function in individuals. The study will evaluate the impact of high dose vitamin D in HIV+ smokers' and HIV- smokers' in vivo. The primary goal is to improve innate immune host response to infection in patients already at high risk by virtue of HIV and smoking status.

Study Overview

• Status: Terminated
• Conditions: HIV/AIDS; Vitamin D Deficiency; Smoker Lung
• Intervention / Treatment: Drug: Vitamin D3 450,000 IU orally

Detailed Description

Tobacco smoke suppresses the lung's ability to fight infection. Smoking is three times more prevalent in the HIV+ compared to HIV- patients. Viral load was found to be significantly increased in HIV+ smokers compared to HIV+ non-smokers, suggesting that smoking enhances HIV-1 viral replication in macrophages, which contributes to disease progression. Vitamin D deficiency has been associated with increased mortality in HIV+ persons, but there is limited research on how this is impacting the health of these highest risk patients and if aggressive repletion with vitamin D can improve overall health.The study team hypothesizes that vitamin D administration will increase pathogen clearance and improve innate immune function.

The proposed pre and post interventional study is designed to characterize alveolar macrophage function and lung immunity according to tobacco use and HIV status, and determine the impact of high dose oral vitamin D3 on AM phagocytic function and innate immunity.

• Study Type: Interventional
• Enrollment (Actual): 7
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Georgia
    • Atlanta, Georgia, United States, 30303
      • Atlanta VA Medical Center
    • Atlanta, Georgia, United States, 30303
      • Grady Health System (non-CRN), Grady Health System (CRN), Ponce Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects living with HIV-1 infection who have been on anti-retroviral therapy (ART) for a minimum of 12 months and are followed longitudinally for their HIV healthcare;
• Ability to give informed consent.

Exclusion Criteria:

• Age <18 yrs old;
• Known or possible pregnancy or breastfeeding;
• Documented history of cirrhosis or a direct bilirubin ≥ 2.0 mg/dL;
• Documentation of left ventricular ejection fraction < 40% or myocardial infarction within the past 6 months;
• End-stage renal disease requiring dialysis or a serum creatinine ≥ 2 mg/d;
• Spirometry with forced vital capacity (FVC) or forced expiratory volume (FEV1)< 70% of predicted value;
• Bleeding disorders such as thrombocytopenia or significant gastrointestinal bleeding within the past year;
• Inability to undergo bronchoscopy safely;
• High risk behaviors without known HIV status.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HIV+ smokers; Vitamin D3 450,000 IU orally	Drug: Vitamin D3 450,000 IU orally; Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
Active Comparator: HIV- non-smokers; Vitamin D3 450,000 IU orally	Drug: Vitamin D3 450,000 IU orally; Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
Active Comparator: HIV+ non-smokers; Vitamin D3 450,000 IU orally	Drug: Vitamin D3 450,000 IU orally; Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
Active Comparator: HIV- smokers; Vitamin D3 450,000 IU orally	Drug: Vitamin D3 450,000 IU orally; Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in alveolar macrophage (AM) phagocytic index between HIV+ smokers compared to HIV- non-smokers.	A phagocytic index will be determined by challenging AM isolated from bronchoalveolar lavage (BAL) to Staph. Aureus in vitro.	Day 1 of the study prior to vitamin D administration.
Difference in phagocytosis percent positive between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.	Difference in phagocytosis percent positive between HIV+ smokers compared to HIV- non-smokers will be calculated.	Day 1 of the study prior to vitamin D administration.
Difference in alveolar macrophage (AM) phagocytic index before and after vitamin D administration.	A phagocytic index will be determined by challenging AM isolated from bronchoalveolar lavage (BAL) to Staph. Aureus in vitro.	Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in total and free vitamin D (25(OH) D) between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.	Difference in total and free 25(OH) D between HIV+ smokers compared to HIV- non-smokers will be measure by ELISA (enzyme-linked immunosorbent assay) levels.	Day 1 of the study prior to vitamin D administration.
Difference in peptide LL-37 between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.	Difference in an antimicrobial and immunostimulating/-modulating peptide LL-37 between HIV+ smokers compared to HIV- non-smokers will be calculated.	Day 1 of the study prior to vitamin D administration.
Difference in tumor necrosis factor alpha (TNF-α) between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.	Difference in tumor necrosis factor alpha (TNF-α) - cytokine involved in systemic inflammation - between HIV+ smokers compared to HIV- non-smokers will be calculated .	Day 1 of the study prior to vitamin D administration.
Difference in messenger ribonucleic acid (mRNA) expression of LL-37 between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.	Difference in mRNA expression of antimicrobial peptide LL-37 between HIV+ smokers compared to HIV- non-smokers will be calculated.	Day 1 of the study prior to vitamin D administration.
Difference in alveolar oxidative stress between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.	Difference in alveolar oxidative stress between HIV+ smokers compared to HIV- non-smokers will be measured using AM isolated from bronchoalveolar lavage (BAL) .	Day 1 of the study prior to vitamin D administration.
Difference in total and free vitamin D (25(OH) D) before and after vitamin D administration.	Difference in total and free vitamin D (25(OH) D) will be measure by ELISA (enzyme-linked immunosorbent assay)	Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration
Difference in peptide LL-37 before and after vitamin D administration.	Difference in peptide LL-37 levels will be calculated.	Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration
Difference in tumor necrosis factor alpha (TNF-α) before and after vitamin D administration.	Difference in tumor necrosis factor alpha (TNF-α) will be calculated.	Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration
Difference in mRNA expression of LL-37 before and after vitamin D administration.	Difference in mRNA expression of LL-37 will be calculated.	Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration
Difference in alveolar oxidative stress before and after vitamin D administration.	Difference in alveolar oxidative stress will be measured using AM isolated from bronchoalveolar lavage (BAL) .	Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration

Collaborators and Investigators

• Sponsor: Emory University
• Investigators: Principal Investigator: Jenny E Han, MD, MSc, Emory University

Study record dates

Study Major Dates

• Study Start (Actual): April 11, 2018
• Primary Completion (Actual): October 15, 2018
• Study Completion (Actual): October 15, 2018

Study Registration Dates

• First Submitted: August 31, 2017
• First Submitted That Met QC Criteria: August 31, 2017
• First Posted (Actual): September 1, 2017

Study Record Updates

• Last Update Posted (Actual): April 21, 2021
• Last Update Submitted That Met QC Criteria: April 19, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Keywords: Immunosuppression; HIV; Smoking; Vitamin D3; Pulmonary disease
• Additional Relevant MeSH Terms: Nutrition Disorders; Avitaminosis; Deficiency Diseases; Malnutrition; Vitamin D Deficiency; Physiological Effects of Drugs; Micronutrients; Vitamins; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Vitamin D; Cholecalciferol
• Other Study ID Numbers: IRB00094833

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No